NOC vs TMO
Northrop Grumman Corp. /DE and Thermo Fisher Scientific Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NOC | TMO |
|---|---|---|
| Revenue | $42.0B | $44.6B |
| Net income | $4.2B | $6.7B |
| Gross margin | 52.8% | 57.1% |
| Net margin | 10.0% | 15.0% |
| Return on equity | 26.2% | 13.0% |
| Diluted EPS | $29.08 | $17.74 |
| Dividend / share | $8.99 | $1.72 |
| Payout ratio | 30.9% | 9.5% |
| Free cash flow | $3.3B | $6.3B |
| Equity | $16.7B | $53.4B |
| Net debt / equity | 0.68× | 0.62× |
| Current ratio | 1.10× | 1.89× |
| Revenue CAGR 5y | 2.7% | 6.7% |
| Profit CAGR 5y | 5.6% | 1.0% |
NOC and TMO book revenue within 15% of each other, and TMO keeps more of each dollar of revenue as profit (15.0% against 10.0%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NOC | TMO |
|---|---|---|
| FY2025 | $42.0B | $44.6B |
| FY2024 | $41.0B | $42.9B |
| FY2023 | $39.3B | $42.9B |
| FY2022 | $36.6B | $44.9B |
| FY2021 | $35.7B | $39.2B |
| FY2020 | $36.8B | $32.2B |
| FY2019 | $33.8B | $25.5B |
| FY2018 | $30.1B | $24.4B |
| FY2017 | $26.0B | $20.9B |
| FY2016 | $24.7B | $18.3B |
Net income by year
Bottom line
| Fiscal year | NOC | TMO |
|---|---|---|
| FY2025 | $4.2B | $6.7B |
| FY2024 | $4.2B | $6.3B |
| FY2023 | $2.1B | $6.0B |
| FY2022 | $4.9B | $7.0B |
| FY2021 | $7.0B | $7.7B |
| FY2020 | $3.2B | $6.4B |
| FY2019 | $2.2B | $3.7B |
| FY2018 | $3.2B | $2.9B |
| FY2017 | $2.9B | $2.2B |
| FY2016 | $2.0B | $2.0B |
Advertisement
AdSense · Rectangle 336×280